{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:30:01Z","timestamp":1787671801103,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":71,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Hospital pharmaceutical research Fund of Jiangsu Province Pharmaceutical Society - Aosaikang","award":["A202345"],"award-info":[{"award-number":["A202345"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Polymyxin B (PMB) is a polypeptide antibiotic primarily used to treat infections caused by multidrug-resistant gram-negative bacteria. Its main adverse effects are neurotoxicity and nephrotoxicity. Neurotoxicity may manifest as irritability, fatigue, lethargy, ataxia, dysgeusia, limb numbness, and blurred vision. Hearing impairment attributed to PMB is rarely reported. Herein, we describe a case of hearing impairment in a patient with renal dysfunction, potentially related to intravenous PMB therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      A 54-year-old, 70-kg male with poorly controlled type 2 diabetes (complicated by nephropathy, neuropathy, retinopathy), end-stage kidney disease (on hemodialysis), and hypertension was admitted to the ICU for gastrointestinal bleeding and hemorrhagic shock. On postoperative day 7, he developed carbapenem-resistant Acinetobacter baumannii (CR-AB) pneumonia and was treated with PMB 50\u00a0mg q12h plus sulbactam 2\u00a0g q8h. Therapeutic drug monitoring (TDM) showed the area under the plasma concentration-time curve across 24\u00a0h at steady state (AUC\n                      <jats:sub>ss, 24\u00a0h<\/jats:sub>\n                      ) of PMB was 37.7\u00a0mg\u00b7h\/L. PMB was increased to 100\u00a0mg q12h, after which the patient reported hearing impairment, with a corresponding AUC\n                      <jats:sub>ss, 24\u00a0h<\/jats:sub>\n                      of 152.8\u00a0mg\u00b7h\/L. The dose was then reduced and subsequently discontinued. The patient\u2019s hearing fully recovered one day after discontinuation. No formal audiologic testing was performed; the diagnosis relied on patient self-report and clinical observation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This case highlights the importance of recognizing neurotoxic events related to PMB, including hearing impairment. Close monitoring and timely intervention are especially critical in patients with renal insufficiency or those receiving high-dose PMB. Accordingly, TDM plays an important role in anticipating and avoiding such adverse reactions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-026-05120-8","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T04:23:09Z","timestamp":1781497389000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Polymyxin B-associated hearing impairment in a patient with renal dysfunction- a case report"],"prefix":"10.1186","volume":"27","author":[{"given":"Xun","family":"Ni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinna","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanhuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"issue":"5","key":"5120_CR1","doi-asserted-by":"publisher","first-page":"e01010","DOI":"10.1002\/prp2.1010","volume":"10","author":"Y Xu","year":"2022","unstructured":"Xu Y, Liang P, Liu N, et al. Correlation between the drug concentration of polymyxin B and polymyxin B-associated acute kidney injury in critically ill patients: A prospective study. Pharmacol Res Perspect. 2022;10(5):e01010.","journal-title":"Pharmacol Res Perspect"},{"issue":"2","key":"5120_CR2","doi-asserted-by":"publisher","first-page":"e01900","DOI":"10.1128\/AAC.01900-20","volume":"65","author":"P Wang","year":"2021","unstructured":"Wang P, Zhang Q, Zhu Z, et al. Comparing the Population Pharmacokinetics of and Acute Kidney Injury Due to Polymyxin B in Chinese Patients with or without Renal Insufficiency. Antimicrob Agents Chemother. 2021;65(2):e01900\u201320.","journal-title":"Antimicrob Agents Chemother"},{"key":"5120_CR3","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.jgar.2020.12.026","volume":"24","author":"ME Falagas","year":"2021","unstructured":"Falagas ME, Kyriakidou M, Voulgaris GL, et al. Clinical use of intravenous polymyxin B for the treatment of patients with multidrug-resistant Gram-negative bacterial infections: An evaluation of the current evidence. Glob Antimicrob Resist. 2021;24:342\u201359.","journal-title":"Glob Antimicrob Resist"},{"issue":"1","key":"5120_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3390\/antibiotics8010031","volume":"8","author":"SN Avedissian","year":"2019","unstructured":"Avedissian SN, Liu J, Rhodes NJ, et al. A Review of the Clinical Pharmacokinetics of Polymyxin B. Antibiot (Basel). 2019;8(1):31.","journal-title":"Antibiot (Basel)"},{"issue":"4","key":"5120_CR5","doi-asserted-by":"publisher","first-page":"229","DOI":"10.4103\/ijp.ijp_762_20","volume":"55","author":"V Simon","year":"2023","unstructured":"Simon V, Viswam A, Alexander PS, et al. Colistin versus polymyxin B: A pragmatic assessment of renal and neurological adverse effects and effectiveness in multidrug-resistant Gram-negative bacterial infections. Indian J Pharmacol. 2023;55(4):229\u201336.","journal-title":"Indian J Pharmacol"},{"key":"5120_CR6","doi-asserted-by":"publisher","first-page":"963140","DOI":"10.3389\/fphar.2022.963140","volume":"13","author":"Y Ning","year":"2022","unstructured":"Ning Y, Chu Y, Wu Y, et al. Case Report: Respiratory paralysis associated with polymyxin B therapy. Front Pharmacol. 2022;13:963140.","journal-title":"Front Pharmacol"},{"issue":"1","key":"5120_CR7","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1590\/2175-8239-jbn-2019-0191","volume":"44","author":"LAM Goldin","year":"2022","unstructured":"Goldin LAM, Silva LN, Silva TFD, Delfino VDA. Polymyxin Acute Kidney Injury: a case of severe tubulopathy. J Bras Nefrol. 2022;44(1):112\u20135.","journal-title":"J Bras Nefrol"},{"issue":"11","key":"5120_CR8","doi-asserted-by":"publisher","first-page":"4742","DOI":"10.1111\/bcp.15384","volume":"88","author":"Y Zhou","year":"2022","unstructured":"Zhou Y, Li Y, Xie X, et al. Higher incidence of neurotoxicity and skin hyperpigmentation in renal transplant patients treated with polymyxin B. Br J Clin Pharmacol. 2022;88(11):4742\u201350.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"5120_CR9","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1136\/ejhpharm-2023-003786","volume":"31","author":"I Bayraktar","year":"2023","unstructured":"Bayraktar I, Halacli B, Demirkan K, Topeli A. Polymyxin B-related neurotoxicity: a brief case report. Eur J Hosp Pharm. 2023;31(1):66\u20137.","journal-title":"Eur J Hosp Pharm"},{"issue":"4","key":"5120_CR10","first-page":"e253959","volume":"16","author":"DN Fitzrol","year":"2023","unstructured":"Fitzrol DN, Ang SY, Suhaimi A, Yeap TB. Rare occurrence of polymyxin B-induced hyperpigmentation in a child with ventriculitis. Case Rep. 2023;16(4):e253959.","journal-title":"Case Rep"},{"key":"5120_CR11","doi-asserted-by":"crossref","unstructured":"Wen X, Luo C, Lyu W. Polymyxin B-induced skin hyperpigmentation. Case Rep Med. 2020;6461329.","DOI":"10.1155\/2020\/6461329"},{"issue":"5","key":"5120_CR12","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1002\/ppul.24727","volume":"55","author":"N Rekis","year":"2020","unstructured":"Rekis N, Ambrose M, Sakon C. Neurotoxicity in adult patients with cystic fibrosis using polymyxin B for acute pulmonary exacerbations. Pediatr Pulmonol. 2020;55(5):1094\u20136.","journal-title":"Pediatr Pulmonol"},{"issue":"3","key":"5120_CR13","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/pcmr.12468","volume":"29","author":"KP Mattos","year":"2016","unstructured":"Mattos KP, Lloret GR, Cintra ML, et al. Acquired skin hyperpigmentation following intravenous polymyxin B treatment: a cohort study. Pigment Cell Melanoma Res. 2016;29(3):388\u201390.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"1","key":"5120_CR14","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/phar.1493","volume":"35","author":"JA Justo","year":"2015","unstructured":"Justo JA, Bosso JA. Adverse reactions associated with systemic polymyxin therapy. Pharmacotherapy. 2015;35(1):28\u201333.","journal-title":"Pharmacotherapy"},{"issue":"2","key":"5120_CR15","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1631\/jzus.B2200466","volume":"24","author":"X Liu","year":"2023","unstructured":"Liu X, Huang C, Bergen PJ, et al. Chinese consensus guidelines for therapeutic drug monitoring of polymyxin B, endorsed by the Infection and Chemotherapy Committee of the Shanghai Medical Association and the Therapeutic Drug Monitoring Committee of the Chinese Pharmacological Society. J Zhejiang Univ Sci B. 2023;24(2):130\u201342.","journal-title":"J Zhejiang Univ Sci B"},{"issue":"1","key":"5120_CR16","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/phar.2209","volume":"39","author":"BT Tsuji","year":"2019","unstructured":"Tsuji BT, Pogue JM, Zavascki AP, et al. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019;39(1):10\u201339.","journal-title":"Pharmacotherapy"},{"issue":"2","key":"5120_CR17","first-page":"214","volume":"57","author":"FEKETYFR CLUFF L E Jr","year":"1962","unstructured":"CLUFF L E FEKETYFR Jr. The treatment of gram-negative bacillary infections with colistin. The toxicity and efficacy of large doses in forty-eight patients. Ann Intern Med. 1962;57(2):214\u201329.","journal-title":"Ann Intern Med"},{"issue":"6","key":"5120_CR18","doi-asserted-by":"publisher","first-page":"857","DOI":"10.7326\/0003-4819-72-6-857","volume":"72","author":"J Koch-Weser","year":"1970","unstructured":"Koch-Weser J, Sidel VW, Federman EB, et al. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med. 1970;72(6):857\u201368.","journal-title":"Ann Intern Med"},{"issue":"2","key":"5120_CR19","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jinf.2021.01.006","volume":"82","author":"X Liu","year":"2021","unstructured":"Liu X, Chen Y, Yang H, et al. Acute toxicity is a dose-limiting factor for intravenous polymyxin B: A safety and pharmacokinetic study in healthy Chinese subjects. J Infect. 2021;82(2):207\u201315.","journal-title":"J Infect"},{"issue":"S1198\u2013743X 20","key":"5120_CR20","first-page":"30764","volume":"2021","author":"F Wagenlehner","year":"2021","unstructured":"Wagenlehner F, Lucenteforte E, Pea F, et al. Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins. Clin Microbiol Infect. 2021;2021(S1198\u2013743X 20):30764\u20133.","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"5120_CR21","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1001\/archneur.1968.00470340088008","volume":"18","author":"MP McQuillen","year":"1968","unstructured":"McQuillen MP, Cantor HE, O\u2019Rourke JR. Myasthenic syndrome associated with antibiotics. Arch Neurol. 1968;18(4):402\u201315.","journal-title":"Arch Neurol"},{"issue":"1","key":"5120_CR22","doi-asserted-by":"publisher","first-page":"R27","DOI":"10.1186\/cc3995","volume":"10","author":"ME Falagas","year":"2006","unstructured":"Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care. 2006;10(1):R27.","journal-title":"Crit Care"},{"issue":"1","key":"5120_CR23","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1021\/acschemneuro.8b00300","volume":"10","author":"C Dai","year":"2019","unstructured":"Dai C, Xiao X, Li J, et al. Molecular Mechanisms of Neurotoxicity Induced by Polymyxins and Chemoprevention. ACS Chem Neurosci. 2019;10(1):120\u201331.","journal-title":"ACS Chem Neurosci"},{"issue":"2","key":"5120_CR24","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1124\/pharmrev.120.000020","volume":"73","author":"SC Nang","year":"2021","unstructured":"Nang SC, Azad MAK, Velkov T, et al. Rescuing the Last-Line Polymyxins: Achievements and Challenges. Pharmacol Rev. 2021;73(2):679\u2013728.","journal-title":"Pharmacol Rev"},{"key":"5120_CR25","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.redox.2015.01.002","volume":"4","author":"H Sies","year":"2015","unstructured":"Sies H. Oxidative stress: a concept in redox biology and medicine. Redox Biol. 2015;4:180\u20133.","journal-title":"Redox Biol"},{"key":"5120_CR26","doi-asserted-by":"publisher","first-page":"784864","DOI":"10.3389\/fphar.2021.784864","volume":"12","author":"N Zhang","year":"2021","unstructured":"Zhang N, Zhu L, Ouyang Q, et al. Visualizing the Potential Impairment of Polymyxin B to Central Nervous System Through MR Susceptibility-Weighted Imaging. Front Pharmacol. 2021;12:784864.","journal-title":"Front Pharmacol"},{"issue":"22","key":"5120_CR27","doi-asserted-by":"publisher","first-page":"16545","DOI":"10.3390\/ijms242216545","volume":"24","author":"WJT Tan","year":"2023","unstructured":"Tan WJT, Vlajkovic SM. Molecular Characteristics of Cisplatin-Induced Ototoxicity and Therapeutic Interventions. Int J Mol Sci. 2023;24(22):16545.","journal-title":"Int J Mol Sci"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-026-05120-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-05120-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-05120-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:52:07Z","timestamp":1787669527000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-026-05120-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5120"],"URL":"https:\/\/doi.org\/10.1186\/s12882-026-05120-8","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"assertion":[{"value":"13 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Nanjing Drum Tower Hospital Group Suqian Hospital (Approval No.: 2024008).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The patient gave permission for publication of this case and data with the written informed consent form.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"495"}}